BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 28088463)

  • 1. Stress-induced EGF receptor signaling through STAT3 and tumor progression in triple-negative breast cancer.
    Balanis N; Carlin CR
    Mol Cell Endocrinol; 2017 Aug; 451():24-30. PubMed ID: 28088463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IL-17E synergizes with EGF and confers in vitro resistance to EGFR-targeted therapies in TNBC cells.
    Merrouche Y; Fabre J; Cure H; Garbar C; Fuselier C; Bastid J; Antonicelli F; Al-Daccak R; Bensussan A; Giustiniani J
    Oncotarget; 2016 Aug; 7(33):53350-53361. PubMed ID: 27462789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
    Blanchard Z; Paul BT; Craft B; ElShamy WM
    Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review.
    Qin JJ; Yan L; Zhang J; Zhang WD
    J Exp Clin Cancer Res; 2019 May; 38(1):195. PubMed ID: 31088482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Salidroside inhibits migration, invasion and angiogenesis of MDA‑MB 231 TNBC cells by regulating EGFR/Jak2/STAT3 signaling via MMP2.
    Kang DY; Sp N; Kim DH; Joung YH; Lee HG; Park YM; Yang YM
    Int J Oncol; 2018 Aug; 53(2):877-885. PubMed ID: 29901185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Binding of galectin-1 to integrin β1 potentiates drug resistance by promoting survivin expression in breast cancer cells.
    Nam K; Son SH; Oh S; Jeon D; Kim H; Noh DY; Kim S; Shin I
    Oncotarget; 2017 May; 8(22):35804-35823. PubMed ID: 28415760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of PRMT1 in EGFR methylation and signaling in MDA-MB-468 triple-negative breast cancer cells.
    Nakai K; Xia W; Liao HW; Saito M; Hung MC; Yamaguchi H
    Breast Cancer; 2018 Jan; 25(1):74-80. PubMed ID: 28643125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Picrasidine G decreases viability of MDA-MB 468 EGFR-overexpressing triple-negative breast cancer cells through inhibition of EGFR/STAT3 signaling pathway.
    Yamashita N; Kondo M; Zhao S; Li W; Koike K; Nemoto K; Kanno Y
    Bioorg Med Chem Lett; 2017 Jun; 27(11):2608-2612. PubMed ID: 28427809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Growth hormone-releasing hormone induced transactivation of epidermal growth factor receptor in human triple-negative breast cancer cells.
    Vacas E; Muñoz-Moreno L; Valenzuela PL; Prieto JC; Schally AV; Carmena MJ; Bajo AM
    Peptides; 2016 Dec; 86():153-161. PubMed ID: 27816751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stat3/Oct-4/c-Myc signal circuit for regulating stemness-mediated doxorubicin resistance of triple-negative breast cancer cells and inhibitory effects of WP1066.
    Cheng CC; Shi LH; Wang XJ; Wang SX; Wan XQ; Liu SR; Wang YF; Lu Z; Wang LH; Ding Y
    Int J Oncol; 2018 Jul; 53(1):339-348. PubMed ID: 29750424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. P53 mutations in triple negative breast cancer upregulate endosomal recycling of epidermal growth factor receptor (EGFR) increasing its oncogenic potency.
    Shapira I; Lee A; Vora R; Budman DR
    Crit Rev Oncol Hematol; 2013 Nov; 88(2):284-92. PubMed ID: 23755891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel small molecule STAT3 inhibitor SLSI-1216 suppresses proliferation and tumor growth of triple-negative breast cancer cells through apoptotic induction.
    Park SK; Byun WS; Lee S; Han YT; Jeong YS; Jang K; Chung SJ; Lee J; Suh YG; Lee SK
    Biochem Pharmacol; 2020 Aug; 178():114053. PubMed ID: 32450253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new synthetic derivative of cryptotanshinone KYZ3 as STAT3 inhibitor for triple-negative breast cancer therapy.
    Zhang W; Yu W; Cai G; Zhu J; Zhang C; Li S; Guo J; Yin G; Chen C; Kong L
    Cell Death Dis; 2018 Oct; 9(11):1098. PubMed ID: 30368518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibiting epidermal growth factor receptor signalling potentiates mesenchymal-epithelial transition of breast cancer stem cells and their responsiveness to anticancer drugs.
    Manupati K; Dhoke NR; Debnath T; Yeeravalli R; Guguloth K; Saeidpour S; De UC; Debnath S; Das A
    FEBS J; 2017 Jun; 284(12):1830-1854. PubMed ID: 28398698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-22 promotes triple negative breast cancer cells migration and paclitaxel resistance through JAK-STAT3/MAPKs/AKT signaling pathways.
    Wang S; Yao Y; Yao M; Fu P; Wang W
    Biochem Biophys Res Commun; 2018 Sep; 503(3):1605-1609. PubMed ID: 30072097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Syndecan-1 is a novel molecular marker for triple negative inflammatory breast cancer and modulates the cancer stem cell phenotype via the IL-6/STAT3, Notch and EGFR signaling pathways.
    Ibrahim SA; Gadalla R; El-Ghonaimy EA; Samir O; Mohamed HT; Hassan H; Greve B; El-Shinawi M; Mohamed MM; Götte M
    Mol Cancer; 2017 Mar; 16(1):57. PubMed ID: 28270211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The radio-sensitizing effect of xanthohumol is mediated by STAT3 and EGFR suppression in doxorubicin-resistant MCF-7 human breast cancer cells.
    Kang Y; Park MA; Heo SW; Park SY; Kang KW; Park PH; Kim JA
    Biochim Biophys Acta; 2013 Mar; 1830(3):2638-48. PubMed ID: 23246576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomic regulation of invasion by STAT3 in triple negative breast cancer.
    McDaniel JM; Varley KE; Gertz J; Savic DS; Roberts BS; Bailey SK; Shevde LA; Ramaker RC; Lasseigne BN; Kirby MK; Newberry KM; Partridge EC; Jones AL; Boone B; Levy SE; Oliver PG; Sexton KC; Grizzle WE; Forero A; Buchsbaum DJ; Cooper SJ; Myers RM
    Oncotarget; 2017 Jan; 8(5):8226-8238. PubMed ID: 28030809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of galiellalactone-based novel STAT3-selective inhibitors with cytotoxic activities against triple-negative breast cancer cell lines.
    Kim HS; Kim T; Ko H; Lee J; Kim YS; Suh YG
    Bioorg Med Chem; 2017 Oct; 25(19):5032-5040. PubMed ID: 28705432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. STAT3 as a promising chemoresistance biomarker associated with the CD44
    Moreira MP; da Conceição Braga L; Cassali GD; Silva LM
    Exp Cell Res; 2018 Feb; 363(2):283-290. PubMed ID: 29352988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.